# SVRA — Savara Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SVRA  
**Sources:** 30  
**Published:** 2026-08-19  
**Canonical:** https://app.k3vl4r.com/research/deep-research-svra-savara-inc-catalysts-narrative-risks-2356

---

# Savara Inc. (SVRA) — Research Summary as of August 19, 2026

## Company Overview

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, headquartered in Langhorne, Pennsylvania [[2]](https://www.biospace.com/press-releases/savara-reports-second-quarter-2026-financial-results-and-provides-business-update)[[24]](https://www.marketbeat.com/stocks/NASDAQ/SVRA/). The company's sole clinical asset is **molgramostim inhalation solution (branded MOLBREEVI)**, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for **autoimmune pulmonary alveolar proteinosis (aPAP)** — a rare, chronic lung disease with no currently FDA-approved therapies [[18]](https://www.tradingview.com/news/zacks:735e78589094b:0-here-s-why-you-should-add-savara-stock-to-your-portfolio-now/)[[20]](https://www.cnbc.com/quotes/SVRA)[[24]](https://www.marketbeat.com/stocks/NASDAQ/SVRA/). Savara is a small-cap company with a market capitalization between $300 million and $2 billion [[30]](https://www.cnn.com/markets/stocks/SVRA).

---

## Key Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-svra-savara-inc-catalysts-narrative-risks-2356 (free to sign up)._